Showing 361 - 377 results of 377 for search 'per monitoring programs', query time: 0.11s Refine Results
  1. 361
  2. 362

    Relationship between physical activity and abdominal obesity and metabolic markers in postmenopausal women by Yangjun Liu, Sujie Mao, Wei Xie, Humińska-Lisowska Kinga Agnieszka, Sawczyn Monika Helena, Dzitkowska-Zabielska Magdalena, Guoping Qian, Zbigniew Ossowski

    Published 2024-11-01
    “…Was included 71 participants from this study program (68.8 ± 4.3 years). We divided participants into LPA and MVPA groups based on their level of moderate to vigorous physical activity per week; Physical activity levels over 7 days were assessed using a POLAR accelerometer, with daily step counts and sedentary time recorded. …”
    Get full text
    Article
  3. 363
  4. 364

    RICD: Russian Intensive Care Dataset by A. V. Grechko, M. Y. Yadgarov, A. A. Yakovlev, L. B. Berikashvili, A. N. Kuzovlev, P. A. Polyakov, I. V. Kuznetsov, V. V. Likhvantsev

    Published 2024-06-01
    “…RICD also contains data on several vital parameters collected from bedside monitors and other equipment of ICUs, with up to 10 evaluations per hour.Conclusion. …”
    Get full text
    Article
  5. 365

    Focused low-intensity hippocampal transcranial ultrasound stimulation (TUS) for sleep disturbances in patients with chronic tinnitus: A study protocol for a pilot randomized contro... by Xi Ni, Yuk Shan Yuen, Zeyan Li, Kaipeng Wang, Natalie Shu Yang, Yi Yuan, Lin Meng, Liwei Guo, Hanna Lu

    Published 2025-01-01
    “…Participants' adherence to the program and any adverse event will be closely monitored throughout the duration of the clinical trial.…”
    Get full text
    Article
  6. 366
  7. 367
  8. 368

    Effects of three months of water-based exercise training on metabolic syndrome components in older women (Efecto de tres meses de entrenamiento con ejercicios acuáticos sobre comp... by Paulina Yesica Ochoa-Martínez, Javier Arturo Hall-López, Daniel Piña Diaz, Diego Armando Zarate Trujillo, Ana Maria Teixeira

    Published 2019-01-01
    “…The training protocol consisted of water-based exercise training sessions 5 times per week during 12 weeks of intervention, executed in a pool of 1.3 meters divided into three phases: a 10-minute warm-up, 30 minutes of aerobic exercise at 50%-60% of maximum heart rate (monitored by heart rate monitor) and a 10 minute cool down. …”
    Get full text
    Article
  9. 369

    État des maraudes et des dégâts de cultures liés aux éléphants à l’ouest du secteur de Djouroutou dans le sud-ouest du Parc National de Taï (Côte d’Ivoire) by F.A. Ouattara, O. Soulemanee, A. Nandjui, E.J. Tondoh

    Published 2010-06-01
    “…Elephant density was estimated to be 1.1 ± 0.7 elephants per km-2 in the sector of the Park bordering the crops. …”
    Get full text
    Article
  10. 370

    Effect of Telemedicine Interventions on Heart Failure Hospitalizations: A Randomized Trial by Edmar G. Ribeiro, Luisa C. C. Brant, Lilian C. Rezende, Regina Bernal, Graziela Chequer, Barbara V. Temponi, Daniel B. Vilela, Julia B. Buback, Renato D. Lopes, Tulio B. Franco, Antonio L. P. Ribeiro, Deborah C. Malta

    Published 2025-03-01
    “…Results were consistent in “per‐protocol” and subgroup analyses. Enrollment was lower than expected because of COVID‐19 disruptions. …”
    Get full text
    Article
  11. 371
  12. 372
  13. 373

    Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study by Lin Shen, Qing Zhou, Ting Sun, Jie Wang, Hongming Pan, Yi-Long Wu, Jun Zhao, Jun Guo, Qingyuan Zhang, Ying Yuan, Yuxian Bai, Tianshu Liu, Yongqian Shu, Siyang Wang, Aiping Zhou, Dingwei Ye, Yujuan Gao, Silu Yang, Zuobai Wang

    Published 2020-05-01
    “…Patients previously treated with therapies targeting PD-1 or its ligand, programmed cell death ligand-1 were excluded. During dose-verification, dose-limiting toxicities (DLTs) were monitored; safety and tolerability were examined and the previously determined recommended phase 2 dose (RP2D) was verified. …”
    Get full text
    Article
  14. 374
  15. 375

    Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context by Suying Lu, Yi Que, Dongyang Liu, Feifei Sun, Xueting Yao, Liting Deng, Jing Zhan, Junting Huang, Ruiqing Cai, Xin Wang, Shixing Zhu, Zijun Zhen, Jia Zhu, Juan Wang, Yizhuo Zhang

    Published 2025-06-01
    “…The primary analysis included all participants who received at least one dose of anlotinib, following the per protocol approach. The safety analysis included all participants who received at least one dose of anlotinib and were monitored for adverse events during the treatment period. …”
    Get full text
    Article
  16. 376
  17. 377

    Global Carbon Budget 2024 by P. Friedlingstein, P. Friedlingstein, M. O'Sullivan, M. W. Jones, R. M. Andrew, J. Hauck, J. Hauck, P. Landschützer, C. Le Quéré, H. Li, H. Li, I. T. Luijkx, A. Olsen, A. Olsen, G. P. Peters, W. Peters, W. Peters, J. Pongratz, J. Pongratz, C. Schwingshackl, S. Sitch, J. G. Canadell, P. Ciais, R. B. Jackson, R. B. Jackson, S. R. Alin, A. Arneth, V. Arora, N. R. Bates, M. Becker, M. Becker, N. Bellouin, C. F. Berghoff, H. C. Bittig, L. Bopp, P. Cadule, K. Campbell, M. A. Chamberlain, N. Chandra, F. Chevallier, L. P. Chini, T. Colligan, J. Decayeux, L. M. Djeutchouang, L. M. Djeutchouang, X. Dou, C. Duran Rojas, K. Enyo, W. Evans, A. R. Fay, R. A. Feely, D. J. Ford, A. Foster, T. Gasser, M. Gehlen, T. Gkritzalis, G. Grassi, L. Gregor, N. Gruber, Ö. Gürses, I. Harris, M. Hefner, M. Hefner, J. Heinke, G. C. Hurtt, Y. Iida, T. Ilyina, T. Ilyina, T. Ilyina, A. R. Jacobson, A. R. Jacobson, A. K. Jain, T. Jarníková, A. Jersild, F. Jiang, Z. Jin, Z. Jin, E. Kato, R. F. Keeling, K. Klein Goldewijk, J. Knauer, J. Knauer, J. I. Korsbakken, X. Lan, X. Lan, S. K. Lauvset, S. K. Lauvset, N. Lefèvre, Z. Liu, J. Liu, J. Liu, L. Ma, S. Maksyutov, G. Marland, G. Marland, N. Mayot, P. C. McGuire, N. Metzl, N. M. Monacci, E. J. Morgan, S.-I. Nakaoka, C. Neill, Y. Niwa, T. Nützel, L. Olivier, L. Olivier, T. Ono, P. I. Palmer, P. I. Palmer, D. Pierrot, Z. Qin, L. Resplandy, L. Resplandy, A. Roobaert, T. M. Rosan, C. Rödenbeck, J. Schwinger, J. Schwinger, T. L. Smallman, T. L. Smallman, S. M. Smith, R. Sospedra-Alfonso, T. Steinhoff, T. Steinhoff, Q. Sun, A. J. Sutton, R. Séférian, S. Takao, H. Tatebe, H. Tatebe, H. Tian, B. Tilbrook, B. Tilbrook, O. Torres, E. Tourigny, H. Tsujino, F. Tubiello, G. van der Werf, R. Wanninkhof, X. Wang, D. Yang, X. Yang, Z. Yu, W. Yuan, X. Yue, S. Zaehle, N. Zeng, N. Zeng, J. Zeng

    Published 2025-03-01
    Get full text
    Article